Search results for "Glycemic"

showing 10 items of 331 documents

Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review

2022

The approval of once daily liraglutide, 3.0 mg, and once weekly semaglutide, 2.4 mg, for chronic weight management provides a novel effective strategy against obesity. The reliable models that might predict weight reducing potential at the individual level have not been identified yet. However, the coexistence of diabetes has been consistently related with less effective response than in people without this comorbidity. We aimed to review the efficacy of GLP-1 RAs approved for weight management in individuals with and without diabetes and discuss some potential mechanisms for consistently observed differences in efficacy between these two populations. The mean weight loss difference between…

Diabetes Mellitus Type 2Glucagon-Like Peptide 1Weight LossGlucagon-Like PeptidesDiabetes GLP-1 RAs Liraglutide Obesity SemaglutideHumansHypoglycemic AgentsPharmacology (medical)ObesityGeneral MedicineLiraglutideWeight GainGlucagon-Like Peptide-1 Receptor
researchProduct

Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections

2022

Dipeptidyl-Peptidase IV InhibitorsDiabetes Mellitus Type 2HumansHypoglycemic Agentsincretins diabetesPharmacology (medical)General MedicineIncretins
researchProduct

[Non-indicated insulin treatment].

1970

171 adult- and aged-onset diabetic patients treated with insulin primarily or secondarily were subjected to an attempted therapy with the additional administration of oral antidiabetic drugs. The new potent antidiabetic drug, glybenclamide (HB 419 = Daonil), was employed on a vast scale in order to carry out an oral monotherapy in the proper indications also combined with biguanides. In the 52 % of patients in study with the additional oral therapy the insulin dose could be remarkably decreased, in the 24 % of cases insulin could be at all abolished. In another 24 % of controlled cases no decrease in insulin need was found. A body weight decrease could be obtained rather in the group of pat…

DrugAdultmedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedia_common.quotation_subjectmedicine.medical_treatmentPharmacologyBody weightInsulin doseEndocrinologyInternal medicineDiabetes mellitusInternal MedicinemedicineDiabetes MellitusHumansHypoglycemic AgentsInsulinShort durationOral therapymedia_commonAgedbusiness.industryInsulinGeneral MedicineMiddle Agedmedicine.diseaseEndocrinologyWeight DecreasebusinessActa diabetologica latina
researchProduct

In vitro and in vivo characterization of a new organic nitrate hybrid drug covalently bound to pioglitazone.

2014

<b><i>Background/Aims:</i></b> Organic nitrates represent a group of nitrovasodilators that are clinically used for the treatment of ischemic heart disease. The new compound CLC-3000 is an aminoethyl nitrate (AEN) derivative of pioglitazone, a thiazolidinedione antidiabetic agent combining the peroxisome proliferator-activated receptor γ agonist activity of pioglitazone with the NO-donating activity of the nitrate moiety. <b><i>Methods:</i></b> In vitro and in vivo characterization was performed by isometric tension recording, platelet function, bleeding time and detection of oxidative stress. <b><i>Results:</i></…

DrugBlood PlateletsMaleBleeding TimePlatelet Aggregationmedia_common.quotation_subjectVasodilator Agentsmedicine.disease_causeMitochondria Heartchemistry.chemical_compoundNitrateFibrinolytic AgentsIn vivomedicineAnimalsHumansHypoglycemic AgentsRats WistarAortamedia_commonPharmacologyNitratesPioglitazoneChemistryGeneral MedicineReactive Nitrogen SpeciesIn vitroOrganic nitratesMice Inbred C57BLVasodilationBiochemistryCovalent bondVasoconstrictionThiazolidinedionesReactive Oxygen SpeciesPioglitazoneOxidative stressmedicine.drugPharmacology
researchProduct

Apical periodontitis and glycemic control in type 2 diabetic patients : cross-sectional study

2020

Background The objective of this study was to analyze the possible relationship between the glycemic control and the prevalence of apical periodontitis in type 2 diabetic patients. The null hypothesis was that apical periodontitis is not associated with glycemic control. Material and Methods In a cross-sectional design, the radiographic records of 216 type 2 diabetic patients (65.0 ± 10.7 years), 117 men (54.2%) and women (45.8%), were examined. Glycated hemoglobin (HbA1c) was used to assess glycemic control, considering an HbA1c level < 6.5% as well-controlled diabetes. Apical periodontitis was diagnosed as radiolucent periapical lesions using the periapical index score. The Student t test…

Endodontic medicinemedicine.medical_specialtyCross-sectional studyRoot canal030204 cardiovascular system & hematologyBlood sugarLogistic regressionGastroenterology03 medical and health scienceschemistry.chemical_compoundDiabetes mellitus0302 clinical medicineApical periodontitisInternal medicineDiabetes mellitusmedicineHemoglobinPeriodontitisGeneral DentistryGlycemicPeriodontitisOral Medicine and PathologyDiabetisHemoglobinabusiness.industryResearchDiabetesGlycated haemoglobin030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]medicine.anatomical_structurechemistryGlucèmiaUNESCO::CIENCIAS MÉDICASGlycated hemoglobinbusinessStudent's t-test
researchProduct

Modulation of Diabetes by Natural Products and Medicinal Plants via Incretins

2019

Incretins are metabolic hormones released after a meal that increase insulin secretion from pancreatic β-cells. The two main incretins are the intestinal peptides glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Both induce a decrease in glycemia, slow down the absorption of nutrients, and are inactivated by the enzyme dipeptidyl peptidase-4. Recently, incretin-based therapies have become a useful tool to treat diabetic patients, and different studies have focused on the identification of glucagon-like peptide-1 receptor agonists, including those of natural origin. This review focuses on the new findings of medicinal plants and natural products as possible active ag…

Enfermedad cardiovascularPharmaceutical SciencePharmacology01 natural sciencesAnalytical Chemistry//purl.org/becyt/ford/1 [https]Tratamiento médicoDPP-4Drug DiscoveryReceptorchemistry.chemical_classificationGIPGLUCAGON-LIKE PEPTIDE-1digestive oral and skin physiologyGlucagon-like peptide-1Diabetes mellitus tipo 2HomeopatíaINCRETINSMolecular MedicineCIENCIAS NATURALES Y EXACTAShormones hormone substitutes and hormone antagonistsendocrine systemOtras Ciencias BiológicasIncretinIncretinsCiencias BiológicasDiabetes mellitusDiabetes MellitusmedicineAnimalsHumansHypoglycemic Agents//purl.org/becyt/ford/1.6 [https]Dipeptidyl peptidase-4PharmacologyBiological ProductsPlants MedicinalGuar gum010405 organic chemistryOrganic ChemistryGLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDEmedicine.diseaseDIPEPTIDYL PEPTIDASE-40104 chemical sciences010404 medicinal & biomolecular chemistryEnzymeComplementary and alternative medicinechemistryGLP-1PhytotherapyHormone
researchProduct

Old and new basal insulin formulations: understanding pharmacodynamics is still relevant in clinical practice.

2013

Long-acting insulin analogues have been developed to mimic the physiology of basal insulin secretion more closely than human insulin formulations (Neutral Protamine Hagedorn, NPH). However, the clinical evidence in favour of analogues is still controversial. Although their major benefit as compared with NPH is a reduction in the hypoglycaemia risk, some cost/effectiveness analyses have not been favourable to analogues, largely because of their higher price. Nevertheless, these new formulations have conquered the insulin market. Human insulin represents currently no more than 20% of market share. Despite (in fact because of) the widespread use of insulin analogues it remains critical to anal…

Evidence-Based Medicinebusiness.industryEndocrinology Diabetes and MetabolismBasal insulinInsulinmedicine.medical_treatmentChemistry PharmaceuticalInsulin Short-ActingType 2 diabetesPharmacologymedicine.diseaseClinical PracticeClinical trialInsulin Long-ActingEndocrinologyDiabetes Mellitus Type 1Diabetes Mellitus Type 2Diabetes mellitusPharmacodynamicsInternal MedicinemedicineHumansHypoglycemic AgentsIn patientbusinessDiabetes, obesitymetabolism
researchProduct

Ammonium formate-Pd/C as a new reducing system for 1,2,4-oxadiazoles. Synthesis of guanidine derivatives and reductive rearrangement to quinazolin-4-…

2021

1,2,4-Oxadiazole is a heterocycle with wide reactivity and many useful applications. The reactive O-N bond is usually reduced using molecular hydrogen to obtain amidine derivatives. NH4CO2H-Pd/C is here demonstrated as a new system for the O-N reduction, allowing us to obtain differently substituted acylamidine, acylguanidine and diacylguanidine derivatives. The proposed system is also effective for the achievement of a reductive rearrangement of 5-(2′-aminophenyl)-1,2,4-oxadiazoles into 1-alkylquinazolin-4(1H)-ones. The alkaloid glycosine was also obtained with this method. The obtained compounds were preliminarily tested for their biological activity in terms of their cytotoxicity, induce…

Formatesquinazolin-4-onemedicine.disease_causeGuanidineschemistry.chemical_compoundBiology (General)CytotoxicityAmmonium formateSpectroscopyOxadiazolesMolecular StructureChemistryAlkaloidBiological activityGeneral MedicineComputer Science ApplicationsChemistryOxidation-ReductionPalladiumCell SurvivalQH301-705.5Dipeptidyl Peptidase 4chemistry.chemical_elementAntineoplastic AgentsreductionArticleCatalysisInorganic ChemistryAmidine4-oxadiazolereduction;Cell Line TumorDiabetes MellitusAmmonium formatemedicineHumansHypoglycemic AgentsReactivity (chemistry)Physical and Theoretical ChemistryMolecular BiologyQD1-999QuinazolinonesSettore MED/04 - Patologia GeneralediacylguanidineOrganic Chemistry124-oxadiazolealpha-GlucosidasesacylguanidineSettore CHIM/06 - Chimica OrganicapalladiumCombinatorial chemistryModels ChemicalA549 CellsOxidative stress
researchProduct

Action of an extract from the seeds of Fraxinus excelsior L. on metabolic disorders in hypertensive and obese animal models.

2014

Nuzhenide and GI3, the principal secoiridoids of an extract obtained from the seeds of Fraxinus excelsior L. (FXE), are believed to be the active compounds responsible for the previously reported hypoglycemic effects of this extract. In this study, the effects of FXE were studied in two animal models which are representative of metabolic disorders: spontaneously hypertensive rats (SHR) and obese Zucker rats. SHR were acutely treated (oral gavage) with different doses of FXE. In addition, SHR and Zucker rats were chronically fed (20 or 5 weeks, respectively) with standard chow supplemented with FXE. Acute treatment with FXE (200 mg per kg body weight) decreased systolic blood pressure as in …

Fraxinus excelsior L.Blood GlucoseMalemedicine.medical_specialtyBlood PressureOral gavageInsulin resistanceInternal medicineRats Inbred SHRmedicineAnimalsHumansHypoglycemic AgentsInsulinObesitybusiness.industryPlant ExtractsHypertriglyceridemiaCaptoprilGeneral Medicinemedicine.diseaseObesityRatsRats ZuckerDisease Models AnimalEndocrinologyFraxinusHypertensionSeedsHypoglycemic EffectsMetabolic syndromebusinessFood Sciencemedicine.drugFoodfunction
researchProduct

Associations of Time in Range and Other Continuous Glucose Monitoring–Derived Metrics With Well-Being and Patient-Reported Outcomes: Overview and Tre…

2021

Time in glucose ranges is increasingly relevant for research and clinical practice. Whereas the clinical validity of these metrics has been demonstrated with regard to long-term complications, their associations with patient-reported outcomes such as well-being, diabetes distress, and fear of hypoglycemia remain an open research question. This article reviews existing evidence on links between times in glycemic ranges and patient-reported outcomes. It also describes a novel research approach of using ecological momentary assessment to analyze on a more granular level in real time possible associations of these parameters of glycemic control and patient-reported outcomes. Such an approach co…

GerontologyContinuous glucose monitoringbusiness.industryEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismHypoglycemiamedicine.diseaseClinical Practice03 medical and health sciencesDistress0302 clinical medicineOpen researchWell-beingFrom Research to PracticeInternal MedicineClinical validitymedicine030212 general & internal medicinebusinessGlycemicDiabetes Spectrum
researchProduct